Remus Pharmaceuticals LtdQ3 FY25
Remus Pharmaceuticals Ltd Q3 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹721P/E: 27.2Market Cap: ₹912 CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
No information is provided regarding the same in the latest conference call.
Margin guidance
No information is provided regarding the same in the latest conference call.
3 more insights locked — sign up free to unlock
Fundraise plans
No information is provided regarding the same in the latest conference call.
Order book
No information is provided regarding the same in the latest conference call.
Capex plans
No information is provided regarding the same in the latest conference call.
How does Remus Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Remus Pharmaceuticals Ltd
See full Pharmaceuticals & Biotechnology sector rankings